Board of Directors
Board of Directors
PRESIDENT
Sally Macaluso
Sally Macaluso is the Vice-President and Chief Procurement Officer for Indirect Services Procurement at Johnson & Johnson. In this role, Sally oversees $14B in spend across a broad remit of Enterprise categories which include Business Services (Corporate Services, HR Services, Fleet/Travel/Meetings, and Information Technology); Capital, Construction, and Facilities Services; Transportation; and Acquisitions & Divestitures. Sally is a member of the Johnson & Johnson Procurement Leadership Team.
Prior to this role, Sally served as the Vice-President and Chief Procurement Officer of Johnson & Johnson MedTech and Business Services Procurement. In this role, Sally was responsible for the Procurement activities for the Johnson & Johnson MedTech sector and the global Enterprise-wide spend in the Business Services categories. Sally was also previously the Vice President of Marketing and Business Services Procurement where she managed $13 billion in spend across the two category families. Sally joined the company as the Vice-President of Johnson & Johnson R&D Procurement with responsibilities for the Enterprise R&D spend.
Sally is very passionate about women’s leadership. She was the Executive Sponsor of the Procurement Women’s Leadership Initiative for five years. She also currently serves as the Executive Sponsor for the Professional Pillar of the Women in Science, Technology, Engineering, Math, Manufacturing, & Design (WiSTEM2D) Program.
Prior to joining Johnson & Johnson in 2012, Sally spent the early part of her career at Merck & Co, Inc. where she held various leadership positions in Procurement.
Sally has a Bachelor’s degree in Chemistry from Bucknell University and a Master’s degree in Chemistry from Lehigh University.
FIRST VICE PRESIDENT
Charles Davies
Mr. Davies is a pharmaceuticals procurement and operations executive with over 20 years of experience in organizational design, strategy development and implementation across direct and indirect categories. He is currently Associate Vice President, Global Sourcing and Procurement for Merck, where he leads the development and execution of procurement strategies supporting Merck’s small molecule business. Prior to joining Merck, he was Vice president, Global Procurement at Teva Pharmaceuticals where he designed, recruited and staffed Global Procurement for Third Party Operations and the Americas region. From 2004-2014 he held various positions at Pfizer and Wyeth (prior to its acquisition by Pfizer), leading global strategic sourcing and API planning teams across EMEA, Americas, and APAC.
Mr. Davies recently served as Third Vice President and on DCAT’s Advisory Council and was a board member of the Philadelphia Drug Exchange, Pharmaceutical Trade Organization. He holds a B.S. in business logistics from Pennsylvania State University, University Park, PA.
SECOND VICE PRESIDENT
Donna Gruol
Donna J. Gruol has been an active champion of the generic pharmaceutical industry throughout her professional career. Ms. Gruol’s passion for the pharmaceutical industry is grounded in cultivating highly collaborative relationships that have significantly improved patient outcomes via access to affordable, lifesaving, and life-enriching medicines. She steadfastly believes in the power of an industry network of professionals from all disciplines that outlives one’s current business card or affiliations – and paying it forward.
Ms. Gruol’s work history includes leadership positions as Vice President, Business Development for XGen Pharmaceuticals DJB, Inc., Director of Business Development for Xellia Pharmaceuticals APS, and progressive positions over a thirteen-year period gained while at Teva Pharmaceuticals. Ms. Gruol brings significant enthusiasm to the industry, backed by a broad range of experience to include leading complex projects and alliances from introduction through commercialization, licensing and business development on a global scale, as well as leadership development initiatives, strategic management and organizational framework, and expansion of critical resource integration via improved supply chain management. She enjoys the challenge of taking an extraordinarily complex industry and breaking it down into four key tenants – clearly defined and manageable processes, purposeful and prompt communication, cultivating talent and freely sharing experiences and relationships within a vast network.
Ms. Gruol is a graduate of the Graziadio School of Business at Pepperdine, University, earning her MBA in Global Organizational Leadership, and holds a BS in Speech, Language Pathology from Marquette University, among other academic pursuits. Previously, she served on DCAT’s Leadership Development Committee, Advisory Council, Alliance for Industry Women Committee, and former Committee Chair of the Membership Advantage Committee.
THIRD VICE PRESIDENT
Kelsey Achenbach
Kelsey Achenbach has been serving the pharmaceutical and specialty chemical industries for more than 20 years, and has a strong passion for improving the lives of patients through partnerships and innovation. Ms. Achenbach has experience in operations management, business development, commercial management, and strategic business transformation. Currently, Ms. Achenbach leads the Global Pharmaceutical and Global Medical Nutrition businesses at dsm-firmenich; leading innovation and development of critical ingredients in parenteral and enteral nutrition while focusing on improving patient access to critical medications. Before joining dsm-firmenich, Ms. Achenbach had extensive experience in supplying and partnering with the pharmaceutical industry; holding strategic leadership roles at Roquette, Celanese, and FMC.
Prior to joining the DCAT Board of Directors, Ms. Achenbach was an active volunteer and advocate for the DCAT organization; holding positions on the Advisory Board and several committees over the past 7 years. Most recently, Ms. Achenbach chaired the Membership Advantage Committee.
In addition to her continued education and certifications in business leadership, Ms. Achenbach holds a B.S. in Chemical Engineering from the University of Minnesota and MBAs from Columbia Business School and London Business School.
DIRECTOR
Camran Aslam
Camran Aslam has more than 16 years of experience within the pharmaceutical industry, which includes a broad range of procurement experience across a portfolio of Registered Starting Materials, Intermediates, APIs, and other direct materials. In his current role as a Director of Procurement at AbbVie, Camran works with more than 90 procurement professionals across 28 manufacturing plants. He is also the Global Category Lead for APIs and Intermediates.
Camran began his procurement career as an Industrial Placement Student at Nissan in Production Procurement and has been an active participant in DCAT Week since 2009. He has also served on the DCAT Supply Management committee since 2020.
Camran holds a Bachelor of Arts in Business Studies from Newcastle Business School, UK and is also MCIPS accredited by the Chartered Institute of Procurement & Supply.
DIRECTOR
Craig Douglas
Craig Douglas has been in the pharmaceutical industry for over 24 years, having served in operational and business development roles for Rhodia ChiRex, Shasun and Siegfried. Currently, as Global Head of Siegfried’s API Portfolio segment, he leads global teams that support business development, customer service and product management activities in over >80 countries. Craig has been an active member of DCAT participating on and serving on the DCAT Education Committee as recently as 2018. He holds a Ph.D in Organic Chemistry from the University of Durham England and a BSc Hons Chemistry from University of Aberdeen Scotland.
DIRECTOR
Scott Price
Scott is a career sales executive with over 22 years of pharmaceutical industry experience. Scott has proudly been with Ren-Pharm international for 16 years and is currently the Vice President of Sales. Ren-Pharm International is an industry leading and globally recognized agent specializing in active pharmaceutical ingredients and the drug development process from R&D through commercialization. Ren-Pharm International represents several industry leading API suppliers, and during Scott’s tenure Ren-Pharm International has been instrumental in identifying API’s and executing strategy to support some of the most highly recognized and highest value ANDA product approvals and first-to-file launches.
Prior to joining Ren-Pharm International, Scott worked for six years with Ortho-McNeil Pharmaceuticals, a Johnson & Johnson Company, holding sales positions of increasing responsibility. Scott graduated from Stetson University with a BS in Business Marketing.
Scott has been an active DCAT volunteer for the past six years as a member of the Science and Scholarship Committee, serving the last five years as the committee chair. Scott was instrumental in developing and participating in DCAT’s primary scholarship initiative as a Special Awards Sponsor for the International Science and Engineering Fair, which provides cash awards to talented and deserving young scientists and future industry leaders.
DIRECTOR
Ken Seufert
Ken Seufert is an accomplished senior executive with over twenty years of experience in strategic leadership positions in the pharmaceutical, nutritional and healthcare industries. Mr. Seufert is currently Chief Executive Officer of JRS Pharma LP and maintains responsibility for all business and manufacturing operations North America. Prior to this role, Mr. Seufert held senior positions in other excipients companies and owned his own businesses. With a focus in oral solid dosage formulation, he has extensive experience in drug formulation and commercializing new products on a global level. He has authored numerous articles on economics, sustainability, and supply chain challenges in the pharmaceutical and nutraceutical industries.
DIRECTOR
Courtney Stanton
Courtney E. Stanton serves as the CEO, Americas and Global Head of Strategy and Sales for Bioseutica, a Netherlands-based Biotechnology Company focused on developing advanced ingredients for the food, feed and medical industries. Prior to Bioseutica, she founded and served as President of Smithfield BioScience and as the Vice President Bioproducts for Smithfield Foods, Inc., a $17 billion global food company founded and headquartered in Smithfield, Virginia.
Prior to joining Bioseutica, Stanton held leadership positions at several large companies in the food industry, including Tate & Lyle, Fonterra U.S.A., and Tyson Foods. Throughout her career, Stanton has served in a variety of business development roles and was responsible for numerous successful ventures into new international markets.
In addition to DCAT, Stanton is a member of TERMIS and the Advanced Regenerative Medicine Institute (ARMI). She serves as an Advisor for the Animal Agtech Innovation Summit and the Georgia Research Alliance and Venture Fund. Passionate about advancing Women’s Health, she is a Board Member of the YWCA of Hampton Roads and on the Executive Leadership Team of the American Heart Association, Virginia. Stanton earned her B.A. in International Relations and Economics from Wellesley College and her MBA from Harvard Business School.
FIRST IMMEDIATE PAST PRESIDENT
Kerri McCullough Wood
Kerri McCullough Wood is currently Senior Vice President and Head of Commercial Teva API and Medis, both global, B2B businesses within Teva Pharmaceuticals, driving profitable and sustainable growth for the organization. Ms. Wood is an accomplished senior executive in the pharmaceutical industry, with over 20 years’ experience, currently managing a P&L in excess of $1 billion. Ms. Wood has a proven track record of developing and implementing the commercial strategy, driving organizational transformation, and leading through uncertainty, while continuing to keep a strong focus on customer centricity and building strong relationships.
Ms. Wood earned an MBA from Fairleigh Dickinson University and holds a B.S. in biology, with a health sciences minor and a pre-medical focus from Boston College. Previously, she served as First Vice President, the chair of DCAT’s Education Committee, and on DCAT’s board as a director.
SECOND IMMEDIATE PAST PRESIDENT
Sean Diver
Mr. Diver has been in the pharmaceutical industry for over 30 years, having served technical and commercial leadership roles for both innovator companies and CDMOs. Currently, he is the Head of East Coast Account Management – Biologics Sales at Lonza. Mr. Diver has been an active member of DCAT for many years participating on various committees, serving as chair of the DCAT Technology Committee, as a member of the Advisory Council, and as a member of the Board of Directors. Mr. Diver holds a B.S. in chemical engineering from Lehigh University.
EXECUTIVE DIRECTOR
Margaret Timony
Ms. Timony currently serves as the Executive Director of the Drug, Chemical & Associated Technologies Association (DCAT). Ms. Timony joined DCAT in December of 1998 after the organization moved its headquarters from New York to New Jersey. During her tenure, she has been responsible for overseeing the strategic direction and operations for the global business development association with active industry volunteers and a staff of 13.
Prior to this, Ms. Timony was the Executive Director of the American Physical Therapy Association of New Jersey (APTAnj) where she was responsible for the management and operations of the 2,500 member professional society which included legislative and regulatory advocacy. During her tenure at APTAnj, she also served concurrently as the executive director of the Acute Care practice section and the Research section for the national APTA organization.
A graduate of Widener University, she is active in association management professional societies and served as a board member and past president of the Middle Atlantic Society of Association Executives. She is also a member of the American Society of Association Executives and has led several small-staffed association group forums and committees.
